NO163867C - Fremgangsmaate for fremstilling av et enzymderivat. - Google Patents

Fremgangsmaate for fremstilling av et enzymderivat.

Info

Publication number
NO163867C
NO163867C NO803304A NO803304A NO163867C NO 163867 C NO163867 C NO 163867C NO 803304 A NO803304 A NO 803304A NO 803304 A NO803304 A NO 803304A NO 163867 C NO163867 C NO 163867C
Authority
NO
Norway
Prior art keywords
procedure
preparation
enzyme derivative
enzyme
derivative
Prior art date
Application number
NO803304A
Other languages
English (en)
Norwegian (no)
Other versions
NO803304L (no
NO163867B (no
Inventor
Richard Anthony Godwin Smith
John Gordon Winchester
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of NO803304L publication Critical patent/NO803304L/no
Publication of NO163867B publication Critical patent/NO163867B/no
Publication of NO163867C publication Critical patent/NO163867C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO803304A 1979-11-05 1980-11-04 Fremgangsmaate for fremstilling av et enzymderivat. NO163867C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7938279 1979-11-05

Publications (3)

Publication Number Publication Date
NO803304L NO803304L (no) 1981-05-06
NO163867B NO163867B (no) 1990-04-23
NO163867C true NO163867C (no) 1990-08-01

Family

ID=10508982

Family Applications (1)

Application Number Title Priority Date Filing Date
NO803304A NO163867C (no) 1979-11-05 1980-11-04 Fremgangsmaate for fremstilling av et enzymderivat.

Country Status (18)

Country Link
US (1) US4808405A (OSRAM)
EP (1) EP0028489B1 (OSRAM)
JP (1) JPS5678590A (OSRAM)
AR (1) AR224786A1 (OSRAM)
CA (1) CA1174621A (OSRAM)
CS (2) CS391991A3 (OSRAM)
DE (1) DE3065190D1 (OSRAM)
DK (1) DK158994C (OSRAM)
ES (1) ES496586A0 (OSRAM)
GR (1) GR72121B (OSRAM)
HK (1) HK65886A (OSRAM)
HU (1) HU185223B (OSRAM)
IE (1) IE50174B1 (OSRAM)
IL (1) IL61408A (OSRAM)
NL (1) NL930029I2 (OSRAM)
NO (1) NO163867C (OSRAM)
NZ (1) NZ195469A (OSRAM)
ZA (1) ZA806641B (OSRAM)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3361610D1 (en) * 1982-04-07 1986-02-06 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
EP0125269A1 (en) * 1982-11-11 1984-11-21 Beecham Group Plc Pharmaceutically active compounds
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5231006A (en) * 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
AU647391B2 (en) * 1989-05-01 1994-03-24 University Of Notre Dame Du Lac, The Methods and materials for expression of human plasminogen in a eukaryotic cell system
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
DE69025934T2 (de) * 1989-05-17 1996-09-19 Res Corp Technologies Inc Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier
CA2027936C (en) 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
GB8928163D0 (en) * 1989-12-13 1990-02-14 Beecham Group Plc Novel treatment
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5187069A (en) * 1990-08-06 1993-02-16 Henry Ford Health System Active site labelling of plasminogen
AU1873092A (en) * 1991-04-09 1992-11-17 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
JP2002507968A (ja) 1997-06-19 2002-03-12 デュポン ファーマシューティカルズ カンパニー 中性のＰ１特異性基を有するＸａ因子阻害剤
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp BINDING CENTERS FOR FIBRIN
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
KR20010000669A (ko) * 2000-10-12 2001-01-05 김기환 스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
BRPI0212726B8 (pt) 2001-09-21 2021-05-25 Bristol Myers Squibb Co compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7459564B2 (en) 2005-01-13 2008-12-02 Bristol-Myers Squibb Company Substituted biaryl compounds as factor XIa inhibitors
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ES2352796T3 (es) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
AU2006261828A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
JP2009539873A (ja) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 抗凝固剤として有用な第ＶＩＩａ因子インヒビターとしての２−アミノカルボニルフェニルアミノ−２−フェニルアセトアミド類
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
AU2008266228A1 (en) 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
PE20091972A1 (es) 2008-05-19 2010-01-15 Schering Corp Compuestos heterociclicos como inhibidores del factor ixa
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
ES2822130T3 (es) 2010-02-11 2021-04-29 Bristol Myers Squibb Co Macrociclos como inhibidores del factor XIa
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
EA023649B1 (ru) 2011-10-14 2016-06-30 Бристол-Майерс Сквибб Кампани ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa
IN2014CN02806A (OSRAM) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
MD20140044A2 (ro) 2011-11-11 2014-08-31 Pfizer Inc. 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
HK1206735A1 (en) 2012-04-06 2016-01-15 辉瑞公司 Diacylglycerol acyltransferase 2 inhibitors
CA2880898A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
HUE032622T2 (en) 2012-08-03 2017-10-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
ES2665153T3 (es) 2013-10-09 2018-04-24 Pfizer Inc. Antagonistas del receptor EP3 de prostaglandina
NO2760821T3 (OSRAM) 2014-01-31 2018-03-10
TWI859674B (zh) 2014-01-31 2024-10-21 美商必治妥美雅史谷比公司 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
TR201809388T4 (tr) 2014-03-17 2018-07-23 Pfizer Metabolik ve ilişkili hastalıkların tedavisinde kullanılmaya yönelik diasilgliserol asiltransferaz 2 inhibitörleri.
EP3536685B1 (en) 2014-04-04 2022-02-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
NO2721243T3 (OSRAM) 2014-10-01 2018-10-20
CU20170134A7 (es) 2015-05-05 2017-12-08 Pfizer 2-tiopirimidinonas
PL3310784T3 (pl) 2015-06-17 2021-03-08 Pfizer Inc. Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
EP3868753B1 (en) 2015-07-29 2022-12-21 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group
WO2017023992A1 (en) 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors
LT3341367T (lt) 2015-08-27 2021-04-26 Pfizer Inc. Biciklinis sulietas heteroarilas arba arilo junginiai kaip irak4 moduliatoriai
WO2017151746A1 (en) 2016-03-02 2017-09-08 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
MA53496A (fr) 2018-08-31 2021-12-08 Pfizer Combinaisons pour le traitement de la stéatohépatite non alcoolique (nash)/maladie du foie gras non alcoolique (nafld) et de maladies associées
ES3039586T3 (en) 2019-05-20 2025-10-22 Pfizer Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178368A (en) * 1971-09-30 1979-12-11 Behringwerke Aktiengesellschaft Method for the treatment of thromboembolism
JPS5325775A (en) * 1976-08-24 1978-03-09 Miller Fluid Power Corp Module type fluid flow control element
US4082612A (en) * 1976-09-24 1978-04-04 Michael Reese Research Foundation Plasminogen activator complex
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

Also Published As

Publication number Publication date
HK65886A (en) 1986-09-12
DK158994B (da) 1990-08-13
AR224786A1 (es) 1982-01-15
IE50174B1 (en) 1986-02-19
DK158994C (da) 1991-01-07
IL61408A (en) 1983-10-31
NO803304L (no) 1981-05-06
GR72121B (OSRAM) 1983-09-16
NO163867B (no) 1990-04-23
JPH0316114B2 (OSRAM) 1991-03-04
JPS5678590A (en) 1981-06-27
DE3065190D1 (en) 1983-11-10
HU185223B (en) 1984-12-28
EP0028489B1 (en) 1983-10-05
ES8204467A1 (es) 1982-05-01
AU6401180A (en) 1981-05-14
NL930029I1 (nl) 1993-06-01
ES496586A0 (es) 1982-05-01
IE802277L (en) 1981-05-05
CS391991A3 (en) 1992-06-17
IL61408A0 (en) 1980-12-31
ZA806641B (en) 1981-10-28
CA1174621A (en) 1984-09-18
DK468880A (da) 1981-05-06
NZ195469A (en) 1984-05-31
NL930029I2 (nl) 1993-12-01
CS391191A3 (en) 1992-08-12
US4808405A (en) 1989-02-28
AU534017B2 (en) 1983-12-22
EP0028489A1 (en) 1981-05-13

Similar Documents

Publication Publication Date Title
NO163867C (no) Fremgangsmaate for fremstilling av et enzymderivat.
NO153202C (no) Fremgangsmaate for fremstilling av et enzymatisk totalhydrolysat fra myseproteiner.
DK373479A (da) Fremgangsmaade til fremstilling af et enzymderivat
NO810765L (no) Fremgangsmaate for fremstilling av farmasoeytisk aktive karbostyrilderivater.
NO803470L (no) Fremgangsmaate for fremstilling av 7-acylamino-3-vinylcefalosporansyrederivater.
NO821676L (no) Fremgangsmaate for fremstilling av et anti-virusaktivt guaninderivat.
NO821087L (no) Fremgangsmaate for fremstilling av cyklobutan-derivater.
FI802267A7 (fi) Menetelmä oksoalkyyli-ksantiinien valmistamiseksi.
NO803591L (no) Fremgangsmaate for fremstilling av fiskemel.
NO794317L (no) Fremgangsmaate for fremstilling av pyrido-indolderivater
FI803547A7 (fi) Menetelmiä uusien piperidyylibentsimidatsolinonien valmistamiseksi.
NO156210C (no) Fremgangsmaate til fremstilling av monacolin k derivater.
NO155693C (no) Fremgangsmaate for fremstilling av eburnamoninderivater.
NO158948C (no) Fremgangsmaate for fremstilling av enzymet kolesterase.
NO156086C (no) Analogifremgangsmaate for fremstilling av substituerte heterocykliske fenoksyaminer.
NO153853C (no) Fremgangsmaate for fremstilling av 17beta-hydroksy-17alfa-pregn-5-en-21-karboksylsyre-gamma-laktoner.
NO152645C (no) Fremgangsmaate for fremstilling av klordioksyd.
NO801142L (no) Fremgangsmaate til fremstilling av klordioksyd.
NO157143C (no) Fremgangsmaate for fremstilling av karbapen-2-em-derivater.
NO802435L (no) Fremgangsmaate til fremstilling av tetrahydrokinolinderivater
NO156653C (no) Fremgangsmaate for fremstilling av et antibiotikum.
NO155539C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme isokinolinderivater.
NO152840C (no) Fremgangsmaate for fremstilling av dibenzyletere.
NO152849C (no) Fremgangsmaate for fremstilling av stivelseslim.
NO160660C (no) Fremgangsmaate for fremstilling av penicillin- eller cefalosporiniminohalogenider.